Medical disclaimer. Retatrutide is investigational — not FDA-approved. That status reflects patent and regulatory timeline (Phase 3 TRIUMPH readouts are ongoing through 2026–2027), not a safety verdict. No retatrutide-specific withdrawal trial has been published. Dosing and protocol language below is educational synthesis built from Phase 2 dose-response data (Jastreboff 2023 NEJM), the TRIUMPH-4 Phase 3 readout (April 2026), and published withdrawal trials of semaglutide (STEP-1 extension, STEP-4) and tirzepatide (SURMOUNT-4). None of it is a clinical recommendation. Decisions about stopping, tapering, or restarting belong with a clinician who knows your history.

Post-GLP-1 Protocol: What to Do After You Stop Retatrutide

You lost the weight. Now the drug is ending — either you are running out of supplier, you hit a dose you do not want to stay on, or you want to see if the change holds. The question is what happens next, and whether there is anything you can do to prevent the regain curve every sema and tirz study has documented.

There is. But the playbook that works is mechanistic, not motivational. Four distinct physiological forces pull weight back up after you stop a GLP-1 agonist. Only one of them is willpower-adjacent. The other three — lean-mass-driven BMR contraction, the specific thermogenic loss that makes retatrutide different from sema and tirz, and set-point hormonal rebound — run on their own timeline regardless of how hard you try.

The reta-specific piece is the fourth force — the glucagon-driven thermogenic loss that sema and tirz users never had and therefore never lose.

Why Weight Comes Back When You Stop Retatrutide

Four forces drive regain after retatrutide — and what to do after stopping retatrutide hinges on addressing each one, not just appetite. Appetite suppression ends as the drug washes out over ~30 days. Lean mass lost during the deficit drops BMR permanently. Retatrutide's glucagon-driven thermogenesis (6–10% REE lift) vanishes. And a compound ghrelin rebound releases simultaneously at stop.

Each force operates on a different timeline and responds to different interventions. Naming them matters because "eat more protein and lift weights" — the standard advice — only addresses force 2.

Force 1: Appetite-suppression withdrawal. Retatrutide has a half-life of ~6 days (Coskun 2022 Cell Metab), meaning the drug washes out over roughly 30 days after your last dose. Gastric emptying returns to baseline. The satiety signal from GLP-1 receptor activation fades. r/Retatrutide threads describe the pattern in timing that aligns with the PK curve: "Around week three, the food noise started creeping back. Not all at once, more like background music slowly getting louder." (r/Retatrutide community post, approximate 2025. Anecdotal — included for texture, not evidence.) If persistent nausea, vomiting, or GI distress extends beyond two weeks after your last dose, see your doctor — that is not the expected withdrawal pattern.

Force 2: Lean mass loss → BMR contraction. In Wilding 2021 STEP-1 (NEJM DEXA substudy, PMID 33567185), approximately 40% of weight lost on semaglutide was lean mass. The retatrutide T2D DXA substudy (Lancet Diabetes Endocrinol 2025, PMID 40609566) reported ~37% lean in diabetic patients, where GIP signaling is blunted — the non-diabetic figure is unpublished and may be more favorable. Every pound of muscle lost drops BMR 6–10 kcal/day. Lose 20 pounds of lean mass and you carry a 120–200 kcal/day permanent tailwind for regain unless you rebuild.

Force 3: Glucagon-axis thermogenic loss [retatrutide-specific]. This is what makes stopping retatrutide different from stopping sema or tirz. Retatrutide's 0.2× glucagon receptor agonism (Coskun 2022) drives resting energy expenditure 6–10% above baseline (Jastreboff 2023 NEJM supplement) and directly oxidizes hepatic fat — the Phase 2 data showed 84% liver-fat reduction at 48 weeks (Jastreboff 2023 NEJM). That thermogenic lift vanishes on discontinuation. Sema and tirz users never had it, so they never lose it. Retatrutide users face a metabolic drop sema/tirz discontinuation protocols do not model.

Force 4: Compound hunger-hormone rebound + set-point defense. After stop, three things converge: hunger that does not quit, a new cold intolerance most readers notice before the scale does, and a fat-loss stall that lifestyle alone does not break. The mechanism is specific to reta, and it is where stopping this drug appears distinct from stopping sema or tirz. #MECHANISTIC_INFERENCE

During treatment, reta suppresses hunger-hormone signaling through two separate paths. The first is insulin-mediated — GLP-1 agonism raises insulin, which lowers ghrelin (insulin-mediated suppression¹). Sema and tirz share this path. The second is brain-mediated — glucagon agonism drives a central signal that lowers ghrelin another 16–22% independently of insulin (central glucagon route²). Reta alone has both. When the drug washes out, both paths release at the same time, on top of the adaptive hormone rise that persists for twelve months after any large weight loss (leptin and ghrelin adaptations remain elevated for ≥12 months, maintaining defense of the highest stable weight — Sumithran 2011, PMID 22029981). The plausible result: a steeper and longer ghrelin rebound than sema or tirz withdrawal at matched weight loss.

The consequence shows up in fat-burning capacity. Over weeks, elevated hunger-hormone tone downregulates fat-burning capacity in brown adipose tissue (BAT UCP1 suppression via vagal-sympathetic withdrawal³). This is a chronic remodeling effect, not an acute drop — a single ghrelin infusion does not change resting metabolic rate (Druce 2009, PMID 19188925). It builds across weeks 4–12 post-stop. Stacked on the lost glucagon-driven REE lift and adaptive thermogenesis, the aggregate post-stop REE deficit is plausibly 15–20% below on-drug baseline. #MECHANISTIC_INFERENCE

The measurement gap matters: no reta trial (Jastreboff 2023, Coskun 2022, Rosenstock 2023, Sanyal 2024, Kanu 2025, TRIUMPH-4 topline) has reported plasma ghrelin. Every quantitative claim above rests on primary data for each arm separately (Hjorth/Hagemann, Arafat, Soule for the receptor-level physiology) and has not been observed directly in reta-treated patients. #GAP_DIRECT_MEASUREMENT Anholm 2014 (PMID 25393640) adds a complicating signal: liraglutide raised total ghrelin 66% over 12 weeks in n=20 T2D, which the authors read as restored circadian rhythm. Total-vs-acyl assay differences and T2D-vs-obesity population effects are candidate reconciliations; the acyl:des-acyl ratio during and after GLP-1 therapy is uncharacterized, and the acyl form is what drives the orexigenic and anti-thermogenic effects. #SOURCE_DISAGREEMENT

Mechanism references (Force 4). ¹ Insulin-mediated ghrelin suppression — GLP-1 raises insulin, insulin lowers plasma ghrelin: Hjorth/Hagemann 2007, PMID 17434608. ² Central glucagon route — glucagon lowers ghrelin ~16–22% in intact humans through a hypothalamic-somatostatin pathway; effect is abolished in hypopituitary patients (confirming the central, insulin-assisted mechanism): Arafat 2005, PMID 16131602; Soule 2005, PMID 16181233; Arafat 2006, PMID 16787987. ³ BAT UCP1 suppression — chronic acyl-ghrelin elevation drives GHS-R1a activation → vagal afferent signaling → sympathetic withdrawal from brown adipose tissue → UCP1 downregulation: Mano-Otagiri 2009, PMID 19351665; Theander-Carrillo 2006, PMID 16767221.

The trial evidence for the regain itself is consistent across class. In Wilding 2022 (STEP-1 extension, Diabetes Obes Metab, DOI 10.1111/dom.14725), participants regained two-thirds of their lost weight within 52 weeks of stopping semaglutide. In Aronne 2024 (SURMOUNT-4, JAMA, PMID 38078870), the maintenance arm diverged from the withdrawal arm by a ~20 percentage-point swing. In Rubino 2021 (STEP-4, JAMA, DOI 10.1001/jama.2021.3224), the 2.4 mg maintenance arm held losses while the placebo-crossover arm regained ~15 percentage points. No equivalent retatrutide withdrawal trial has been published. The mechanism predicts a similar or steeper curve.

Can You Stop Retatrutide Cold Turkey?

Yes — there is no physical withdrawal syndrome. But cold-turkey discontinuation sets up regain. Appetite returns over weeks 3–6, lean mass lost during the deficit is already gone, and retatrutide's glucagon-driven thermogenic lift vanishes with no replacement. Tapering to a maintenance dose for 8–12 weeks gives time to build training volume and install peptide support before the drug leaves.

The PK data (Jastreboff 2023 NEJM supplement) is clear: stopping retatrutide abruptly does not produce a withdrawal syndrome in the neurological sense. You will not feel acutely sick from the absence of the drug. What you will feel — over 3 to 6 weeks as it washes out — is the return of your pre-drug appetite architecture, in a body with less muscle and no glucagon-driven metabolic lift to compensate.

The purpose of tapering is not pharmacological (retatrutide does not need to be stepped down for receptor reasons). It is behavioral and metabolic. A taper gives you 8–12 weeks of lower-but-still-present appetite suppression in which to rebuild lean mass, install the peptide bridge, and lock in the eating and training patterns that have to hold once the drug is gone.

The Retatrutide Taper: Maintenance Dose and Step-Down Protocol

The retatrutide maintenance dose is typically 2–4 mg weekly SubQ — roughly one-third to one-half of peak trial doses (8–12 mg). The 4 mg arm in Jastreboff 2023 Phase 2 achieved ~17% weight loss, confirming the dose retains metabolic effect. No retatrutide withdrawal trial has been published; these numbers extrapolate from SURMOUNT-4 (tirzepatide maintenance) and STEP-4 (semaglutide maintenance) plus Phase 2 dose-response data.

A three-phase taper structure:

The 2–4 mg maintenance range is not clinician-endorsed — no withdrawal trial has been published for retatrutide. It is extrapolated from two anchor points. First, the Phase 2 4 mg arm in Jastreboff 2023 (NEJM) achieved ~17% weight loss — meaningful metabolic effect at roughly half the peak dose without the GI and cardiac load of 8–12 mg. Second, maintenance logic from SURMOUNT-4 (tirzepatide 5–10 mg maintenance preserved weight loss vs placebo withdrawal) and STEP-4 (semaglutide 2.4 mg maintenance held losses) supports the general pattern: roughly one-third to one-half of peak dose retains the effect.

What to monitor during the taper:

• Weight: weekly, same conditions (morning, fasted, post-void).
• Waist circumference: biweekly — visceral fat is the metric that tells you whether the glucagon-axis effect is holding or regressing.
• Resting heart rate: biweekly. Expect a 2–4 bpm drop through the taper as glucagon-driven cardiac stimulation fades. If resting HR drops more than 10 bpm or you experience dizziness, see your doctor.
• Hunger (1–10 scale): daily morning check — tracks the weeks 3–6 food-noise return curve.
• Strength: big-three lifts (squat, bench, deadlift) tracked weekly. Strength trend is the leading indicator of lean-mass preservation.
• Fasting glucose + lipids: weeks 4 / 12 / 24 — catches metabolic drift before the scale does.

For low-dose reconstitution math during the step-down phase, the GLP-1 dosing calculator handles conversions, and the reconstitution guide covers the mechanics of drawing sub-milligram doses accurately.

The Peptide Bridge: Replacing What Retatrutide Did

Retatrutide did four things mechanically. Stopping the drug removes all four at once. The peptide bridge replaces three of them — and actively undoes the fourth (the lean-mass loss that every GLP-1 agonist creates as a side effect).

Tesamorelin replaces the metabolic heavy lifting retatrutide's glucagon axis was doing. Stanley 2019 (Lancet HIV) showed tesamorelin reduces visceral adipose tissue and liver fat through pulsatile GH release — the same liver-fat target retatrutide was hitting through a different receptor. Dose: 1–2 mg nightly SubQ, rotating injection sites. Deep coverage in the tesamorelin guide and protocol architecture in Retatrutide Dual-Axis.

MOTS-c addresses the mitochondrial flexibility question — whether your cells can still switch efficiently between fat and glucose fuel once the glucagon drive is gone. Lee 2015 (Cell Metab) characterized MOTS-c as a mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity. Dose: 5–10 mg twice weekly SubQ. See the MOTS-c guide.

NAD+ is the cofactor capacity layer. Beta-oxidation (fat burning at the mitochondrial level) depends on NAD+ availability. Yoshino 2021 (Cell Metab) maps the biology. Dose: 100–200 mg five times weekly SubQ or IM. The companion article Retatrutide + NAD+ Protocol covers the sequencing logic during active dosing; the bridge phase uses the same framework with retatrutide removed. Broader context in the NAD+ guide.

Start the bridge during Phase 1 of the taper — not after. The point is to have replacement signaling already established before retatrutide washes out, not to scramble into it once weight is already moving the wrong direction. For sequencing logic across multiple peptides, the peptide stacking guide covers timing and compatibility.

Optional add-ons: BPC-157 during the GI-transition window (weeks 3–8) for gut-axis normalization as gastric motility returns. L-carnitine stacked with fasted training to support CPT-1 fat transport.

Resistance Training and Protein: The Non-Negotiables

To avoid regain after stopping retatrutide, eat ≥1.6 g/kg protein distributed across 3–4 meals daily (Mozaffarian 2025 AJCN) and train with resistance 3–5 sessions per week emphasizing compound lifts. Muscle preservation is the single biggest lever — every pound of lean mass retained is 6–10 kcal/day of BMR that does not drop. Start from week 1 of the taper, not after.

The lean-mass data across the GLP-1 class is consistent and uncomfortable. Wilding 2021 STEP-1 DEXA: ~40%. Aronne 2022 SURMOUNT-1: ~25% (tirzepatide's GIP agonism does more lean-preservation work). Retatrutide T2D DXA (Lancet Diabetes Endocrinol 2025, PMID 40609566): ~37% in diabetic patients — non-diabetic data unpublished. Mass General Brigham clinician guidance and the Mocciaro 2025 GLP-1 lean mass review both land on the same intervention: resistance training plus high protein intake, started during active dosing, carried through the transition.

Protein target: ≥1.6 g/kg body weight daily (Mozaffarian 2025 AJCN — the consensus "protein priorities" recommendation for muscle protein synthesis during weight change). Distribute across 3–4 meals with 30–50 g each. Leucine threshold matters more than total intake at any single meal.

Training: 3–5 sessions per week. Compound lifts (squat, deadlift, press, row, pull-up). Progressive overload from week 1 of the taper. Cardio in a supporting role — not a replacement. The active LEAN Mass RCT (NCT06885736) is testing resistance-training interventions specifically during GLP-1 discontinuation; no results yet.

Deeper coverage in GLP-1 Lean Mass.

Managing the Ghrelin Surge: Four Non-Pharmacologic Levers

Once retatrutide washes out, the compound ghrelin release described in Force 4 has to be managed behaviorally — no ghrelin antagonist exists clinically (PF-05190457 was shelved). These four levers are convergent sympathetic-nervous-system support to BAT during the UCP1-unsupported weeks 4–12 window. None of them replace the pharmacologic effect. They each address one node in the chain.

1. Protein timing + leucine threshold every 3–4 hours. Ghrelin oscillates on a ~3–4 hour cycle. Eat at the troughs, not through them — 30–50 g protein per meal, ≥3 g leucine each, four meals a day. Protein is the most satiating macronutrient and transiently suppresses ghrelin acutely (Mozaffarian 2025 AJCN, consensus protein-priorities statement, already anchoring H2-6 above). This works with the oscillation instead of against it.

1. Bitter pre-meal compounds. TAS2R bitter taste receptors in the gut mediate an acute ghrelin-suppressive signal (Janssen 2011, PNAS, PMID 21368216). 10–15 mL bitter tincture (gentian, wormwood, artichoke) 10 minutes pre-meal is the common-practice dose. #evidence-light — the TAS2R-ghrelin mechanism is established, but specific clinical dosing for post-GLP-1 rebound has not been trialed.

1. Fasting-mimicking schedule. Front-load calories early in the day and compress the eating window to 8–10 hours. This works with the ghrelin oscillation rather than fighting it, and aligns eating with the circadian peak of insulin sensitivity. Mechanism-based, not formally trialed in post-GLP-1 discontinuation.

1. Cold exposure. Acyl-ghrelin downregulates BAT UCP1 through sympathetic withdrawal (Mano-Otagiri 2009). Cold exposure does the opposite — van der Lans 2013 (J Clin Invest, PMID 23708878) showed 10 days of cold acclimation recruited BAT and raised non-shivering thermogenesis in healthy adults. 10–15 minutes of cold exposure (cold shower finish, cold plunge, or sub-15°C ambient) 3–5×/week during weeks 4–12 directly counters the UCP1 suppression arm.

These are convergent supports, not pharmacologic replacements. The bridge peptides still do the metabolic heavy lifting; these four make the behavioral layer match the biology.

Timeline: What to Expect Week-by-Week After Your Last Dose

If resting HR drops more than 10 bpm from baseline or you experience dizziness, fainting, or chest discomfort at any point in this window, see your doctor — that is outside the expected pattern.

The weeks 5–8 convergence, explained. This window is where three independent biological timelines overlap. Meta-analytic GLP-1 regain onset lands at ~8 weeks (eClinicalMedicine 2025). BAT UCP1 remodeling under chronic acyl-ghrelin elevation builds across weeks 4–12 (Mano-Otagiri 2009; Tsubone 2005). And the compound ghrelin release — both arms, plus Sumithran — is peaking against a body still short on lean mass. Subjectively this shows up as peak hunger, new cold intolerance, and thermogenic sluggishness — the cold intolerance is often the first signal readers miss because they are watching the scale and not their thermoregulation. The tools for this window are the four non-negotiables in H2-6: protein timing on ghrelin oscillation, bitter pre-meal compounds, fasting-mimicking schedule, and deliberate cold exposure to recruit BAT while UCP1 is downregulated.

Fatigue during this window is real and mostly metabolic, not psychological — the body is adjusting to a lower thermogenic baseline with less NAD+ turnover efficiency than active dosing. The GLP-1 fatigue article covers the pattern and the specific NAD+ and MOTS-c timing that blunts it.

When to Restart vs Stay Off

This is a decision framework, not a prescription. Restart decisions belong with a clinician who knows your history.

Red-flag criteria — evaluate low-dose restart:

• >5% weight regain over 8 weeks despite protocol adherence
• Visceral fat markers (waist, DXA VAT) rebounding despite tesamorelin
• HbA1c drift above your pre-drug baseline
• Training strength declining month-over-month despite protein and session consistency

Green-flag criteria — stay off:

• Weight stable ±3 lb over 12 weeks
• Strength trending up (big-three lifts progressing)
• Glucose + lipid panels stable or improving
• Subjective energy and food-noise levels manageable

Restart, if indicated, is typically at the 2–4 mg maintenance band — not at peak dose. The goal is to re-install mechanical support, not repeat the original aggressive titration. Restarting is a tool, not a failure — the set-point biology behind Sumithran 2011 is a twelve-month story, and some people simply need longer pharmacological assistance than a single 18-month cycle.

How This Translates to Semaglutide and Tirzepatide

The four-force framework holds across the GLP-1 class. Only force 3 — the glucagon-axis thermogenic loss — is retatrutide-specific. Everything else is compound-agnostic. Dose numbers and bridge-priority shift per compound.

Sema users face a pure appetite + lean-mass story — no thermogenic drop to compensate for. Tesamorelin priority rises because sema did less lean-preservation work on the way down. Tirz users face a mild GIP-driven insulin-efficiency reduction post-stop, but no thermogenic collapse — the best lean-preservation profile of the three. Deeper coverage in semaglutide and tirzepatide.

What the Evidence Actually Shows (and Doesn't)

What is trial-backed:

• Regain curve after discontinuation — Wilding 2022 STEP-1 extension, Rubino 2021 STEP-4, Aronne 2024 SURMOUNT-4.
• Lean-mass fraction of weight lost — Wilding 2021 STEP-1 DEXA, SURMOUNT-1 DEXA, retatrutide T2D DXA 2025.
• Persistent hormonal adaptations at 12 months — Sumithran 2011 NEJM.
• Retatrutide Phase 2 dose-response and Phase 3 TRIUMPH-4 efficacy — Jastreboff 2023 NEJM, TRIUMPH-4 April 2026 readout.

What is mechanism-inferred:

• Retatrutide-specific glucagon-axis thermogenic loss on discontinuation. The mechanism is established (Coskun 2022, Jastreboff 2023); the withdrawal dynamic is extrapolated.
• The peptide bridge as a replacement layer. Each component has individual trial support (tesamorelin for visceral fat, MOTS-c for mitochondrial biology, NAD+ for cofactor capacity), but the integrated protocol has not been tested in a post-GLP-1 transition RCT.

What is unknown:

• Whether retatrutide's 0.2× glucagon agonism produces a sharper or gentler regain curve than pure GLP-1 agents. No retatrutide withdrawal trial has been published. TRIUMPH readouts through 2026–2027 are ongoing; off-drug extension data is not yet available.
• Non-diabetic lean-mass fraction on retatrutide. The only DXA data is diabetic (37%). GIP is blunted in T2D — non-diabetic numbers could shift meaningfully.
• Whether the peptide bridge, as protocolized here, replicates the integrated effect retatrutide was producing. The claim is mechanistic: each layer addresses a specific force in the regain chain. Whether the sum approximates the parts is a hypothesis until an RCT tests it.
• Plasma ghrelin on retatrutide — not measured in any trial. Jastreboff 2023 NEJM Phase 2, Coskun 2022 Cell Metab, Rosenstock 2023 T2D, Sanyal 2024 MASLD, Kanu 2025, and the TRIUMPH-4 Phase 3 topline readout (April 2026) all omit plasma ghrelin as an endpoint. The compound-suppression frame in Force 4 is mechanistic inference stacked on human primary data for each arm separately (Arafat/Soule for glucagon, Hjorth for GLP-1) — not a direct observation in reta-treated patients. #GAP_DIRECT_MEASUREMENT Anholm 2014 (PMID 25393640) adds a complicating signal: liraglutide raised total ghrelin 66% over 12 weeks in n=20 T2D, which the authors interpreted as restored circadian rhythm. Possible reconciliations include total-vs-acyl assay differences, T2D vs obesity population effects, and counter-regulatory response to weight loss. The acyl:des-acyl ratio during and after GLP-1 therapy is uncharacterized — and the acyl form is what drives the orexigenic and anti-thermogenic effects. #SOURCE_DISAGREEMENT

Until TRIUMPH withdrawal data lands, the retatrutide post-stop protocol is mechanistic inference — the most coherent synthesis currently available, not trial-validated.

FAQ

Can you stop retatrutide cold turkey?
Yes, there is no withdrawal syndrome. But cold turkey sets up regain — appetite returns weeks 3–6, lean mass is already gone, glucagon thermogenesis vanishes with no replacement. Taper instead.

What is the retatrutide maintenance dose?
Typically 2–4 mg weekly SubQ — about one-third to one-half of peak trial doses. Extrapolated from Phase 2 dose-response (Jastreboff 2023) and SURMOUNT-4 / STEP-4 maintenance logic. No retatrutide withdrawal trial has been published.

How long does retatrutide stay in your system after stopping?
Half-life is ~6 days (Coskun 2022). Full pharmacological washout takes approximately 30 days from the last dose. Appetite-suppression effects fade over that window.

Do you gain weight after stopping retatrutide?
Without a protocol, yes — Wilding 2022 STEP-1 extension showed two-thirds regain at 52 weeks on semaglutide. With a protocol (taper, training, peptide bridge), weight typically holds. The mechanism, not the willpower, is what determines the outcome.

Does retatrutide stop food noise permanently?
No. Food noise returns 3–6 weeks after the last dose as gastric emptying normalizes. This is consistent across the class.

When do you get your muscle back after a GLP-1?
Resistance training plus ≥1.6 g/kg protein during the taper is the faster path. Meaningful lean-mass recovery typically takes 12–24 weeks of consistent progressive overload — the body needs a signal to rebuild, and that signal is repeated mechanical tension under load.

Do you need tesamorelin and NAD+ to come off retatrutide?
No. The bridge is a mechanism-driven upgrade, not a requirement. Tapering + training + protein alone will outperform cold turkey. The bridge addresses the specific metabolic gaps (glucagon thermogenic loss, beta-oxidation capacity) that sema/tirz protocols do not have to solve.

Should I restart retatrutide if I gain weight back?
Not a yes/no. Use the red-flag / green-flag criteria above and involve a clinician. Restart is typically at the 2–4 mg maintenance band, not peak dose.

How does retatrutide discontinuation differ from semaglutide or tirzepatide?
Sema post-stop is pure appetite + lean-mass. Tirz post-stop adds a mild GIP-insulin-efficiency drop but no thermogenic collapse. Retatrutide post-stop is the only one where the glucagon-driven REE lift and hepatic fat oxidation vanish — this is the force-3 distinction.

What about blood sugar after stopping retatrutide?
Fasting glucose and HbA1c can drift upward over weeks 8–16 if lean mass is not preserved. Check at weeks 4 / 12 / 24. Drift above pre-drug baseline is a red-flag criterion.

Is the "reta stopped working" plateau the same as tolerance?
Probably not. True receptor tolerance to GLP-1 agonists is not well-characterized in the literature. Plateaus typically reflect metabolic adaptation (lower BMR after weight loss, increased caloric efficiency) rather than receptor desensitization. The fix is usually a training / protein / peptide-bridge audit, not a dose increase.

Do I need to change my diet when I stop?
Yes — appetite returns over weeks 3–6, and the meal patterns that held during active dosing (smaller portions, delayed eating) no longer hold automatically. Anchor on protein front-loading at breakfast, fiber with every meal, and pre-planned portions for at least the first 16 weeks.

Related Topics

• Retatrutide — mechanism, dosing, Phase 3 TRIUMPH data
• Retatrutide Dual-Axis — tesamorelin architecture
• Retatrutide + NAD+ Protocol — cofactor layer
• GLP-1 Fatigue — metabolic fatigue during taper
• GLP-1 Lean Mass — muscle preservation deep-dive
• Tesamorelin, MOTS-c, NAD+ Guide
• Semaglutide, Tirzepatide — cross-compound
• Peptide Stacking Guide
• GLP-1 Dosing Calculator, Reconstitution Guide, Retatrutide Dosing Tool